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Abstract
Background: Patients with HIV/AIDS on Antiretroviral Therapy (ART) suffer from physical, psychological and spiritual
problems. Despite international policy explicitly stating that a multidimensional approach such as palliative care
should be delivered throughout the disease trajectory and alongside treatment, the effectiveness of this approach
has not been tested in ART-experienced populations.
Methods/design: This mixed methods study uses a Randomised Controlled Trial (RCT) to test the null hypothesis
that receipt of palliative care in addition to standard HIV care does not affect pain compared to standard care
alone. An additional qualitative component will explore the mechanism of action and participant experience.
The sample size is designed to detect a statistically significant decrease in reported pain, determined by a two
tailed test and a p value of ≤0.05. Recruited patients will be adults on ART for more than one month, who report
significant pain or symptoms which have lasted for more than two weeks (as measured by the African Palliative
Care Association (APCA) African Palliative Outcome Scale (POS)). The intervention under trial is palliative care
delivered by an existing HIV facility nurse trained to a set standard. Following an initial pilot the study will be
delivered in two African countries, using two parallel independent Phase III clinical RCTs. Qualitative data will be
collected from semi structured interviews and documentation from clinical encounters, to explore the experience
of receiving palliative care in this context.
Discussion: The data provided by this study will provide evidence to inform the improvement of outcomes for
people living with HIV and on ART in Africa.
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Background
In 2009, the global number of people with HIV was 33.3
million (95% CI 31.4 million- 35.3 million) with the
majority in sub Saharan Africa, where 22.5 million adults
and children live with HIV infection [1]. Improved treat-
ment and care programs are urgently required [2].
Despite recent treatment guideline changes, which have
raised the recommended CD4 threshold for initiation
of antiretroviral therapy (ART) [3] (indicating that the
population of ART patients should be expected to
increase), the World Health Organization (WHO) reports
that the number of eligible patients receiving treatment
has increased from 28% in 2008 to 36% in 2009 world-
wide. Under the previous treatment guidelines, this pro-
portion would have been 52% in 2009 [4]. This increase in
the number of eligible patients will become a mounting
clinical challenge.
Studies in Brazil [5], Malawi [6], USA [7], UK [8] and
South Africa [9] demonstrate that people living with
HIV continue to experience a significant symptom bur-
den after ART initiation. This was clearly demonstrated
by a large UK study of HIV outpatients [10], who
reported physical, psychological and global distress and
symptom counts which remained unaffected by treat-
ment status, suggesting that accessing effective treat-
ment for the virus might not be sufficient to alleviate
suffering. The prevalence of symptoms and associated
distress in this patient group can be caused by toxicities
from the ART itself [11-13], symptoms of opportunistic
infections and co-morbidities or HIV disease [7,10,14].
People with HIV report lower quality of life [6,15-17],
attributed to their physical and psychological symptom
burden. In Australia, patients with HIV receiving ART
had a significantly higher prevalence of depression when
compared with HIV negative patients recruited from the
same clinics [18]. Data from a UK study confirm this,
with psychological distress reported by 75% of a sample
of HIV outpatients, regardless of treatment status [8]. In
Sweden, although physical health status improved after
ART initiation, patients reported a deterioration in emo-
tional quality of life, associated with an increase in the
number of adverse reactions they experienced [19]. In
Tanzania 53% of patients attending a clinic (of whom
the majority were receiving ART), had palliative care
needs [20].
Palliative care is defined by the WHO [21] as an essen-
tial component of care for people living with HIV. Pallia-
tive care includes the assessment and treatment of pain
and other symptoms, whether physical, psychosocial or
spiritual in nature, delivered alongside treatment. Lead-
ing experts have highlighted the false dichotomy of pal-
liative care treatment versus cure, particularly among
the vulnerable poor in developing countries [22-27]. The
WHO clearly identifies an urgent need for holistic
palliative care integrated with treatment for those suffer-
ing from chronic diseases such as HIV. This has been
reiterated by UNAIDS, which has identified the mis-
conception that palliative care is only appropriate for
patients at the end of life, and is therefore working
towards the availability of palliative care for all people
living with HIV [28].
The WHO public health model of palliative care,
developed in 1990, integrates palliative care into all of
society, from community level to expert palliative care
provision and in existing healthcare structures [29].
However, the pioneering service provision attempts and
advocacy for this model are hampered by a lack of
experimental research, and a lack of standardised mea-
sures and protocols, which would facilitate a more
robust approach to healthcare evaluation and delivery
[30]. For successful implementation, the WHO public
health model of palliative care needs robust evidence of
effectiveness in relevant contexts.
There are wider reasons beyond patient quality of
life that indicate the importance of attention to palliative
care-related problems. Depression and treatment of
side effects are associated with non-adherence to ART
[31,32], which increases viral resistance, rebound and
infectiousness [33]. A recent systematic review of pallia-
tive care-related problems at HIV diagnosis identified
significant physical and psychological symptoms among
newly diagnosed HIV positive patients [34]. A systematic
review of the evidence for effectiveness of HIV palliative
care found that it improves anxiety, pain, symptoms,
and insight but that the evidence was generated almost
exclusively in the pre-ART era and in high income coun-
tries [24]. There are currently no known trials of pallia-
tive care for patients with HIV on ART. This lack of
evidence originating from low and middle-income coun-
tries is problematic in light of the great disease burden
in these areas.
We therefore aim to inform HIV service provision
by conducting a randomised controlled trial (RCT) to
assess the effectiveness of palliative care for HIV outpati-
ents on ART, and present here the protocol for the
phase III RCT with a qualitative component.
Methods/design
Aim and objectives
Aim
We aim to evaluate the efficacy, in terms of reported
pain of a nurse led palliative care intervention for HIV
patients on ART. Nurses will receive two weeks in depth
training in palliative care and support and supervision
from an experienced palliative care mentor. Two trials
are being conducted, one in Mombasa, a low-income
setting, and one in Cape Town, a middle-income setting.
In line with guidance from the Medical Research
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Council (MRC) on the evaluation of complex interven-
tions, qualitative data will also be collected to comple-
ment the quantitative data and address the question of
how the intervention might work [35].
Objectives
1. To investigate whether self-report pain and
symptoms significantly improve for HIV positive
patients under palliative care compared to those in
standard HIV care.
2. To compare self-report adherence to ART under
palliative care compared to standard HIV care.
3. To compare self-report health-related quality of life
under palliative care compared to standard HIV care.
4. To compare additional multidimensional palliative
care outcomes (psychological, social and spiritual
wellbeing) under palliative care compared to
standard HIV care.
5. To understand the process of receiving palliative care
and identify any specific component which may be
the most effective aspect (i.e. access to strong
analgesia, multidimensional assessment, access to
multidisciplinary team).
Study design
The study will consist of two fully powered, independent
phase III clinical RCT’s preceded by a pilot. Each trial
will be powered and conducted in parallel to a common
research design protocol, thus providing evidence of out-
comes in two different settings.
Patients will be randomly allocated to standard HIV
care or standard HIV care plus palliative care. The pal-
liative care will be delivered within the existing HIV
clinic, and by existing staff, using an integrated model,
with the option to refer to a specialist palliative care pro-
vider for complex cases. The study has been designed
with measures to minimise potential contamination.
Once the study nurses have been trained in palliative
care, they will only see the patients allocated to the
intervention, and will not be required to work in the
main clinic until completion of the trial.
The design will be longitudinal, using repeated mea-
sures. Patient-centred outcomes will be measured using
quantitative questionnaires.
Outcomes
The primary outcome is self-reported pain after four
months. The secondary outcomes are health-related
quality of life; adherence to treatment; risk behaviours;
and psychological morbidity and the core domains of
palliative care as defined by the WHO (physical, psycho-
logical, social and spiritual well-being) as measured by
the APCA African POS.
Patients will be followed up for four months and most
outcomes are measured at baseline and monthly inter-
vals, described below.
Control
Patients randomly allocated to the control arm will
receive the usual clinical care delivered by the HIV
clinic. Nurses who have had no exposure to palliative
care will provide this service.
In Kenya this consists of six-monthly clinical assess-
ments once ART has been established, with investiga-
tions and treatment for any relevant symptoms or
problems. Patient may attend the clinic for medications
refill only or may request more frequent appointments
if they experience a problem. In South Africa, patients
attend the public hospital monthly for a brief appoint-
ment to refill medications. They may present for add-
itional appointments as necessary.
Intervention
Patients randomly allocated to the intervention arm
will receive clinical care from a nurse who has received
two weeks’ training in palliative care and ongoing clin-
ical support and supervision from experienced palliative
care providers. The palliative care trained nurse will also
have the option to refer complex cases for management
at a hospice.
Minimum package of palliative care
Patients allocated to the intervention arm will receive an
initial clinical assessment , followed by either one further
visit or phone call within the first week, one further visit
or phone call within the second week and one visit per
month thereafter. The focus of the care provided will
be on holistic assessment and management of physical,
psychological, spiritual and social problems. This min-
imum package of care can be supplemented by additional
clinical support as required on a case-by-case basis.
Intervention nurse training
Training will be provided by local expert palliative care
sites, and will be delivered in an intensive 2-week period,
tailored to the needs of patients living with HIV who are
not necessarily in advanced stages and who are currently
on ART.
The training will be designed using national and inter-
national guidelines [36,37] to ensure that the nurses are
prepared to address the specific palliative care dimen-
sions and needs of those living with HIV and taking
ART, with specific focus on the management of common
HIV symptoms. Within these two weeks, the nurses
will also gain clinical experience, working in a palliative
care setting.
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Standardised assessment form
Assessment and management of multidimensional pro-
blems is a central part of palliative care. The trained
nurse will use a standardised assessment form, devel-
oped by the study team drawing on tools and models
used in sub Saharan Africa, to assess the domains
of palliative care as defined by the WHO [21] and moni-
tor adherence.
Clinical support
The nurse will receive weekly clinical support from an
experienced palliative care provider, where all cases will
be reviewed and decisions appraised. Drugs needed for
the intervention group not stocked in the study site
pharmacy will be dispensed by the supporting palliative
care service.
Referral
As part of clinical support, referral to the hospice will be
available for patients in the intervention arm whose
needs are “complex” or apparently refractory and who
require assessment or intervention from the palliative
care specialist partner site. Criteria for referral will be
established prior to the study launch, and recorded in
the clinical documentation.
Sample size
We used the largest known dataset generated by the
APCA African POS (detailed below) to derive expected
levels of change used in the sample size calculation. The
dataset consisted of baseline data from a longitudinal
evaluation of care and support which recruited 1337
HIV patients in Uganda and Kenya [38]. Stata v10.0 was
used for calculations.
Sample size was first calculated based on change in
the pain item of the APCA African POS, as the primary
outcome. A clinically significant change in an APCA
African POS item is a change of 1 point so this is identi-
fied as the expected change [39]. We propose a sample
size of 56 per arm to be able to demonstrate a difference
between treatment conditions for pain, symptoms,
and both physical and psychological dimensions of qual-
ity of life (the latter as a mediating variable in a model
of adherence). The study will recruit 60 patients per
arm (120 total in each country), allowing for 6% drop-out/
attrition [40].
Settings
The two participating HIV care facilities (one in Kenya
and one in South Africa) are highly experienced HIV
and ART service providers, with proven longevity. The
study site in Kenya is a private clinic funded by private
donations in a deprived area of Mombasa. Regular
appointments are made to see a nurse for a health check
and ART refill, with frequency dependant on adherence,
opportunistic infections and CD4. Patients have access
to a physician if referred by the triaging nurse, and good
access to essential medicines. The South African study
site is a government-run clinic in district township,
south-east of Cape Town. Patients have monthly
appointments for a health check and ART refill, and
have similar access to clinic physicians as in Kenya –
upon nurse referral. Access to essential medicines is
mostly reliable, but is hampered by economic constraints
necessitating short prescriptions. In both countries,
the providers of the palliative care training and support
are longstanding local experts. In Kenya, training was
provided by Kenyan Hospice and Palliative Care Asso-
ciation (KEHPCA) with support from an expert from
Coast Hospice in Mombasa. In South Africa, training
was provided by Hospice Palliative Care Association
(HPCA) and support was provided by an expert from
Helderberg Hospice.
Recruitment and consent
Screening and recruitment Because of organisational
and logistical differences between the two study sites,
recruitment will be performed in a slightly different way,
whilst maintaining the integrity of random sampling and
respecting the logistical constraints, patient flow and
unique pressures of each clinic.
In Kenya, the initial patient to be screened will be
chosen randomly using the number allocated to them
at registration that day, and a number selected from
a random number table. Once the initial patient has
been screened, patients will be screened consecutively.
In South Africa patients are simply screened consecu-
tively according to the order in which they present at
the clinic.
Inclusion/exclusion criteria
In both countries, patients included in the study must
be adult patients (i.e. aged 18 years or above), with
known HIV infection who have been receiving ART for
more than one month.
Patients meeting these criteria will be screened by a
researcher, using first two items of the APCA African
POS. If they report a score of 3, 4 or 5 on either (pos-
sible 0–5 score), they will be asked whether they have
been experiencing the pain or symptoms for 2 weeks or
longer. Patients who answer in the affirmative will be eli-
gible for participation. This is in order to identify those
with symptoms which suggest a chronic rather than
acute problem. The researcher will then outline the
study content and demands and ask whether they would
like to consent to participate. This process will take
place every day during the data collection period,
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although the time of the day will vary randomly in order
to collect a representative sample of the clinic population.
In Kenya, potential participants will be screened for
eligibility from a list of all patients currently in the clinic,
in the triage room of the comprehensive care unit,
where all HIV positive patients are seen. In South Africa,
all patients in the clinic are HIV positive and on ART,
therefore the researcher will sit in the clinic room with
the nurse and will screen each potential participant as
they attend their appointment. All patients who are
called to see the nurse will be screened consecutively
and invited to consent if eligible.
In summary, to be eligible for participation, patients
must have sufficient cognitive ability to answer the
outcome tool questions using either verbal or hand
responses (see data collection below), be receiving ART
for at least one month (based on clinic records) and
must report either pain or symptoms of 3, 4 or 5 on the
APCA African POS (i.e. severe to overwhelming) for
longer than two weeks. Exclusion criteria include pain
and symptoms with a duration of less than 2 weeks,
receiving ART for Prevention of Mother To Child
Transmission (PMTCT) of HIV, or for some other rea-
son not related to personal clinical need or if the patient
does not speak either English or Kiswahili in Kenya, and
English, isiXhosa or Afrikaans in South Africa.
Consent
If eligible, the patient is taken through the information
and consent sheet in a separate private space, respecting
the patient flow of the clinic and the demands on patient
time. Patients will have an information sheet read aloud
to them, and will then be asked to sign or mark a con-
sent form. All information and consent forms will be
translated into the principal local languages. Consent
using either a signature or mark will be obtained accord-
ing to local custom or patient preference. All consent
forms will be kept securely at the facility, and stored sep-
arately from outcome data. Each patient will be allocated
a unique identifying number, kept by the researcher.
All participants will have the right to withdraw, with-
out notice, at any point. Participants who withdraw from
the intervention arm will continue to receive the inter-
vention for the full four months. They will be asked
whether they want their data to be withdrawn. If so, it
will be deleted from the database and the paper copy
will be destroyed. After quantitative data collection has
finished, the dataset will be anonymised and from that
point it will no longer be possible to identify individuals
and withdraw data.
A record of the number of patients not agreeing to
participate will be kept at each facility in accordance with
CONSORT guidelines for the reporting of RCTs [41].
The sample for the qualitative interviews will be pur-
posively drawn from intervention (n=20) and control
patients (n=10) based on the clinical and demographic
patient characteristics and results of the quantitative
data collection i.e. psychological well-being. This will
attempt to ensure a representative sample in terms of
demographic and clinical data, and also in terms of psy-
chological well-being and response to the intervention.
Randomisation
Consenting patients will be administered the initial as-
sessment and subsequently randomised to intervention
or control group. This is done using block randomisa-
tion to ensure a manageable work load for the nurse
delivering the intervention, with 40 per block. Each
study site has been issued with three sealable pots con-
taining 20 pieces of paper with “I” for intervention and
20 pieces of paper with “C” for control. Once a piece of
paper has been blindly selected by the researcher, the
patients is informed whether they are in the control or
intervention group and this is recorded on a form which
is kept separately from the data collection tools and
records. The piece of paper is discarded and the process
continues until the pot is finished, when the next pot is
then used. The allocation to control or intervention is
not blinded as it would be impossible to maintain this
blinding when the intervention was delivered.
Compensation
Study participants are not given financial compensation
for their time, but they are given $5USD towards trans-
port expenses for data collection appointments. Trans-
port for intervention patients clinical appointments
(of which there are at least two more than research
appointments) are not reimbursed as this may influence
the outcome. For comfort, participants are given a
drink and small snack on arrival for their data collec-
tion appointments.
Ethical considerations
Ethical approval has been sought and secured from
Kings College London Research Ethics Committee
(BDM/10/11-31), University of Cape Town (019/2011),
Ministry of Health of the Western Cape (Research
request ID: 10252) and Kenyan Medical Research Insti-
tute (KEMRI/RES/7/3/1).
A distress protocol will be used, with participants being
offered the opportunity to cease the interview if they be-
come distressed during questioning. They will be able to
decide to restart or abandon the interview at their own
discretion. All information gathered during data collec-
tion will be confidential, except in the situation of a par-
ticipant or someone related to the participant being at
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risk, in which case the information will be acted upon.
Please see Figure 1 for study flow chart.
Data collection and analysis
Data will be collected by local researchers following the
study protocol. They will be trained in quantitative
and qualitative data collection methods, and will receive
specific training for each tool used in this study.
Tools
The data collection tools are:
Patient demographic record
Administered once only, at month 0 This brief record
will be used to record age, gender, couple status, number
of children, number of financial dependents, education,
recent CD4, date of ART initiation, WHO staging data
and whether the patient is receiving TB treatment. This
questionnaire also includes assessment of relative socio-
economic status, as used in the Demographic Health
Surveys [42].
APCA AFRICAN POS (10 items)+ eastern Co-operative global
performance scale (ECOG) (1 item)
Administered at months 0, 1, 2, 3 and 4 The original
Palliative Outcome Scale (POS) was developed at King’s
College London [43,44] (further information and
resources are available at http://pos-pal.org/). The APCA
African POS was culturally adapted from the original
POS during development in ten centres in six sub-
Saharan African countries [45]. The ten items of the
APCA African POS address the primary physical, emo-
tional and spiritual concerns of patients and families
with progressive disease using a scoring method appro-
priate for a range of literacy skills. Each item is scored
on a scale of 0–5, and can be scored verbally or using
Figure 1 Study flow chart.
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the “hand” method commonly used in Africa. Using this
method, a closed fist represents “0”, moving up to an
open hand scoring “5”. These methods have been vali-
dated among 300 patents under palliative care in Africa
with a correlation of around 0.9 for verbal vs hand scor-
ing methods for both pain scores and symptom scores.
For those with no family carer, family items are scored
as “0”, i.e. no problem [45]. The tool is sensitive to
change and acceptable to patients, family and staff. Its
brief nature makes it highly appropriate for use in a
large-scale longitudinal study [46].
The ECOG is a single item measure of performance and
is the most widely used performance measure [47].
Scores range from 0 (normal activity) to 4 (unable to get
out of bed). It has been used in previous work amongst
HIV positive people in Africa [48].
Medical outcome study -HIV (MOS-HIV quality of
life measure)
Administered at months 0, 1, 2, 3 and 4 The MOS-
HIV was originally developed as a general health ques-
tionnaire in the USA [49]. A modified HIV-specific
version was developed and widely used. It has been cul-
turally adapted to the Ugandan HIV setting [50] and has
been used in Rwandan [51] Zimbabwean [52] and Ugan-
dan populations [53]. The 35 items address the domains
of role function, pain, physical functioning, cognitive
functioning, social functioning, general health percep-
tion, mental health, health distress and vitality.
General health questionnaire-12 (GHQ)
Administered at months 0, 1, 2, 3 and 4 The GHQ-12
is a widely used measure of psychological morbidity
[54]. It is the shortest validated version of the original
GHQ, which was a 60-item instrument when it was
first designed in the 1970s [55]. The GHQ-12 has been
translated and validated into many languages including
Kenyan Kiswahili [56].
Adherence and risk questionnaire
Administered at months 0, 2 and 4 only The adher-
ence and risk questionnaire has been used for research
in the UK, predominately with gay men [10,57]. The risk
section of the questionnaire consists of three questions
detailing sexual partners in the past four months, detail-
ing unprotected sex and unprotected sex with people
of unknown HIV status. The adherence questions asks
participants how many ART doses they have missed in
the past week.
Client services receipt inventory (CSRI)
Administered at months 0, 1, 2, 3 and 4 The CSRI
aims to explore the components of care received by
patients. The version of the CSRI used in this study is
based was adapted from versions used in other palliative
care research and adapted for use in Africa [58,59]. The
version used for this study has been simplified in that in-
stead of documenting time, the researcher records
whether the client has received a service or not as a
binary outcome.
Qualitative interview schedule
Administered for selected patients at month 4 The
interview schedule was developed in collaboration with
international researchers experienced in HIV and pallia-
tive care research and local researchers with an in depth
knowledge of the delivery of palliative care at the study
sites. It is designed to explore the intervention and con-
trol patients’ perspectives on participating in a rando-
mised trial, the intervention patients’ experiences of
receiving palliative care, and to determine the potential
mechanism of action of the intervention.
Piloting
All tools were professionally translated into local lan-
guages and checked for consistency and accuracy by
local researchers in each country and piloted with 35
patients in Kenya. This checked for clarity of questions,
time required for data collection, patient burden and
availability of requested information.
Quantitative data collection
Data collection will be conducted in the usual place of
care, i.e. at home or at the clinic. For all tools, data will
be collected as close as possible to the monthly time-
table, with a two week grace period either side. Data col-
lection appointments will be co-ordinated with clinical
appointments where possible for minimal patient
disruption.
Qualitative data collection
The qualitative data collection will be conducted be-
tween one and four months after quantitative data col-
lection finishes, to minimise recall bias. Interviews will
be digitally recorded and translated and transcribed by
experienced local experts. Each transcription will be
checked and validated by the researcher who conducted
the interview.
Data management and quality assurance
A researcher will be employed at each participating
centre. This person will be responsible for managing
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recruitment, data collection and data entry. Fortnightly
study team conference calls will be used to ensure that all
queries are promptly resolved, attended by all members.
All quantitative data will be double-entered into pur-
pose designed EpiData databases. Discrepancies will be
resolved by referring back to the original questionnaires.
Following data checking and cleaning, the data will
be imported into Stata for analysis at KCL. Qualitative
transcripts will be imported into NVivo (version 9)
for analysis. All hard data will be stored for at least
seven years in accordance with the UK Data Protection
Act 1998.
Analysis
Quantitative analysis
Data will be described in two stages:
1) Cross sectional baseline analysis: descriptive analysis
of demographic and clinical variables, baseline
primary and secondary outcomes for the two groups
(standard care and palliative care). Continuous
variables will be presented as mean (standard
deviation), median (range); categorical variables will
be described as proportions. Baseline scores for
primary and secondary outcome variables for two
groups will be compared using two-sample t-test
(or Mann–Whitney U test if non-normal
distribution) for continuous data and Chi square
test for categorical data.
2) Summary measures: change in primary and
secondary outcomes from baseline to the final time
point will be summarized, using paired t-tests or
the non-parametric equivalent.
Longitudinal analysis will be performed to address the
primary study objectives of comparing pain and other
symptoms, (objective 1) and subsequently adherence
(objective 2), health related quality of life (objective 3)
and multidimensional palliative care outcomes such as
psychological and spiritual well-being (objective 4), in
the intervention and control groups. Factors of the
APCA African POS were identified from APCA POS
data from similar samples (high prevalence of HIV) in
Sub Saharan Africa [60]. Three factors were identified
which covered 1) physical and psychological symptoms,
2) interpersonal dimension and 3) the existential dimen-
sion. They will be analysed for differences between inter-
vention and control groups. For continuous outcomes,
the change in scores for two groups will be compared
using general linear model with adjustment of baseline
differences and covariates (demographics and clinical
variables). For categorical outcomes, the two-group
comparisons will be implemented using generalized lin-
ear model and adjusting for design effects, the repeated
measures will be taken into account using generalized
estimating equations (GEE) technique.
The analysis will follow the principle of intention-to-
treat. The p-values reported will be two-tailed and an
alpha level of 0.05 will be used to assess statistical
significance. The analysis will be carried out using non-
missing data. The pattern of missing data and drop-outs
will be investigated and sensitivity analysis will be
performed to assess their impacts on outcomes. If the
impact is great, a missing data strategy will be put in
place using mean horizontal imputation and last value
carried forward.
Further descriptive analysis will be conducted to deter-
mine the common features and differences between the
three palliative care facilities, and the services received
as recorded in the CSRI. Analysis of the CSRI will also
allow us to determine a dosage effect for receipt of
palliative care, as well as allow an evaluation of the
palliative care received with respect to outcomes.
Qualitative analysis
Analysis of translated transcripts will be conducted using
thematic content analysis [61]. The coding frame will be
developed initially deductively, using themes from the
topic guide, combined with inductive themes which
emerge from the data, which will be generated iteratively
as the analysis progresses. The coding will be conducted
separately by two researchers, one from the study site
and one from the UK, and then merged, to ensure a
comprehensive and culturally sensitive framework.
The preliminary findings will be cross checked by the
researcher based at the study site and presented to the
study team in each country for proxy member checking
to improve validity [62].
A model of the mechanism of the psychosocial aspect
of palliative care will be constructed on the basis of the
data if possible and relevant.
Dissemination
The audience for dissemination will include collaborat-
ing centres, participants, HIV clinicians, academic teach-
ing staff in Africa, local community groups and non-
governmental organisations, academic global research
audiences, Ministries of Health and international non-
governmental organisations.
Discussion
The data provided by this study will provide evidence
to inform the provision of palliative care for people
living with HIV and on ART, building on our previous
work describing the palliative care problems of this
group [8,10,24,46].
Aspects of this study are unique and will contribute to
the body of knowledge. The choice of study design, the
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first RCT in this field, will provide a clear answer to the
question of whether palliative care for this group is
effective and relevant. The multi-country aspect will illu-
minate the differences between low and middle income
countries, and Southern and Eastern Africa, without
inviting direct comparison of outcomes of two very
different countries. Researchers in both countries will be
locally recruited and trained by staff from King’s College
London, building local capacity. Steps have been taken
to reduce potential bias, including using locally validated
tools, which have been translated in all three study
languages by experienced translators. Researchers have
been trained on aspects of data collection, bias mini-
misation and potential sources of contamination and
data will be double entered to avoid inaccuracies from
human error.
The publication of this protocol presents increased
transparency in the aims and objectives of the study and
analysis of the generated data.
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